Skip to main content
Premium Trial:

Request an Annual Quote

Novogene, AITbiotech to Launch Joint Venture, New Sequencing Center

NEW YORK (GenomeWeb) – The sequencing service center Novogene and molecular diagnostics and services company AITbiotech will form a new joint venture called NovogeneAIT Genomics Singapore, and will establish a whole-genome sequencing center in Singapore.

The new center will provide whole-genome sequencing and bioinformatics based on Illumina's HiSeq X instruments, and will support public research projects and large-scale sequencing initiatives in Singapore and the broader region. It will also collaborate with the Genome Institute of Singapore to use whole-genome sequencing for cancer diagnosis and to identify treatments based on patients' molecular profile.

In addition, NovogeneAIT and GIS will work to develop new applications for next-generation sequencing.

"The center is the first major project for NovogeneAIT and is an important milestone for our company," Novogene CEO Ruiqian Li said in a statement.

GIS Executive Director Ng Huck Hui added, "Such public-private partnerships will prove to be highly beneficial as it leverages the strengths of both parties to advance genomic science and medicine in Singapore, as well as to create successful local biotech companies."

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.